- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Year in Review: Updates in DLBCL Treatment | Supplements and Featured Publications
Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm
October 05, 2020
Article
Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.
Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL
September 30, 2020
Article
Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.
Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma
September 29, 2020
Video
John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.
Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL
September 23, 2020
Video
Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.
Dr. Balzarotti on the Challenges of Treating Elderly DLBCL
September 18, 2020
Video
Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.
Dr. Pagel on the Evolution of Treatment in DLBCL
September 16, 2020
Video
John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.
Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm
September 09, 2020
Article
Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.
Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL
September 07, 2020
Article
Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.
Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL
September 02, 2020
Video
Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.
Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL
August 31, 2020
Article
Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.
Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL
August 18, 2020
Video
John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.
Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL
August 13, 2020
Video
John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.
FDA Approvals Augment Advances Made in the DLBCL Armamentarium
August 11, 2020
Article
John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.